Novartis CEO Says US China Biotech Curbs Risk Drug Development
Novartis AG Chief Executive Officer Vas Narasimhan said proposed US restrictions on biotech investments in China could hamper the development of new medicines.
Aggregator site: only the publisher's summary is shown here. Read the full story at the source.
Read full story →